16 Dec 2021 Valneva Announces Positive Homologous Booster Data for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
15 Dec 2021 European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
15 Dec 2021 Sumitomo Dainippon Pharma Oncology Provides Update on Phase 3 WIZARD 201G Study of Ombipepimut-S Emulsion (DSP-7888) in Patients with Recurrent or Progressive Glioblastoma
15 Dec 2021 Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation
11 Dec 2021 Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update
08 Dec 2021 I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease
07 Dec 2021 Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
06 Dec 2021 Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate
06 Dec 2021 Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses
03 Dec 2021 Valneva Confirms Initiation of Rolling Review with EMA and Provides Updates on its COVID-19 Vaccine Program VLA2001
02 Dec 2021 Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates
02 Dec 2021 VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults
02 Dec 2021 U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
27 Nov 2021 Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
22 Nov 2021 Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
21 Nov 2021 Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
21 Nov 2021 Akston Biosciences Doses First Subjects in Phase II Clinical Trial in India of Second-Generation COVID-19 Vaccine
17 Nov 2021 Daiichi Sankyo Initiates Phase 2 Trial of mRNA Vaccine Against COVID-19 (DS-5670) in Japan
16 Nov 2021 Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate
14 Nov 2021 AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer’s Vaccine Generates a Potent Immune Response
12 Nov 2021 Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03
11 Nov 2021 Inventprise Announces Investment of up to $90 Million to Advance its 25 Valent Pneumococcal Conjugate Vaccine Candidate into Proof-of-Concept Clinical Trials
10 Nov 2021 Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2
05 Nov 2021 Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years
04 Nov 2021 Uvax-2129, a Recombinant Protein Nanoparticle Vaccine, Uvax Bio’s Answer to COVID-19, Shows Great Promise Against Variants of Concern

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up